Intracameral Implants — CPB 1065 | AETNA Coverage Update

Aetna modified CPB 1065 for intracameral implants, effective January 16, 2026. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its intracameral implants coverage policy under CPB 1065 to establish medical necessity criteria for two specific drug-eluting implants: bimatoprost (Durysta) and travoprost (iDose TR). The policy directly affects HCPCS codes J7351 and J7355, along with CPT codes 0660T, 0661T, and 66030. If your practice bills for glaucoma procedures or ophthalmic drug delivery, this coverage policy change affects your prior authorization workflow and claim submission process starting January 16, 2026.

Quick-Reference Table

Aetna Intracameral Implant Coverage Criteria and Medical Necessity Requirements 2026

The core of this Aetna intracameral implants coverage policy is a strict step-therapy requirement. Both Durysta and iDose TR are one-time treatments. Aetna will not cover a second implant in the same eye — ever. That's not a documentation issue you can fix. It's a hard stop built into the policy.

To get medical necessity approval for bimatoprost (Durysta) under HCPCS J7351, your patient must meet all six of the following criteria:

For travoprost (iDose TR) under HCPCS J7355, the criteria are nearly identical:

These criteria require documented trial-and-failure of two separate drug classes before Aetna considers either implant medically necessary. That means your chart documentation must show both a prostaglandin failure and a beta-blocker failure or contraindication — before the implant date. Retroactive documentation won't support the claim.

The prescribing or supervising physician must be an ophthalmologist. A referral or consultation with an ophthalmologist satisfies this requirement, but that relationship needs to be clear in the record.

Prior authorization is almost certainly required for these procedures given the step-therapy criteria. Confirm your prior auth workflow for J7351 and J7355 before scheduling the procedure. If you're unsure how prior authorization applies to your specific Aetna plan contracts, check with your billing consultant or Aetna provider relations before January 16, 2026.

Aetna Intracameral Implant Exclusions and Non-Covered Indications

Aetna draws a sharp line here. Any indication not explicitly covered is considered experimental, investigational, or unproven. Two situations are explicitly excluded.

All other indications for intracameral implants — meaning any diagnosis code or clinical scenario outside of open-angle glaucoma (ICD-10 H40.10X0–H40.159) or ocular hypertension (H40.51–H40.59) — are not covered. Don't attempt to bill J7351 or J7355 for off-label uses. The claim denial is automatic.

Combined travoprost (iDose TR) intracameral implantation with cataract surgery is specifically called out as experimental. Aetna states that the effectiveness of this combined approach has not been established. This is a significant carve-out for practices that perform both procedures in the same surgical session. If your surgeon implants iDose TR during cataract surgery, Aetna will not reimburse the iDose TR component under this policy. The cataract surgery itself isn't affected — but CPT 0660T paired with cataract surgery codes will face denial under this policy.

The real issue here is that combined procedures are increasingly common in glaucoma management. This exclusion puts Aetna out of step with how some ophthalmologists are using iDose TR clinically. If your surgical volume includes combined cases, audit those claims now and talk to your compliance officer before submitting.

Coverage Indications at a Glance

Aetna Intracameral Implant Billing Guidelines and Action Items 2026

1. Confirm prior authorization before scheduling.
Both J7351 (bimatoprost) and J7355 (travoprost) are high-cost drugs with strict step-therapy requirements. Assume prior auth is required for every Aetna patient. Check the specific plan contract — but don't assume auth isn't needed just because the surgical request is.

2. Document both drug class failures in the chart before the procedure date.
You need documented trial-and-failure of a topical prostaglandin AND a topical beta-blocker (or a contraindication to the beta-blocker). That documentation must exist in the record before the implant date of service, not added after. A missing prior failure note is the most common reason these claims deny.

3. Flag combined iDose TR and cataract surgery cases immediately.
If your practice schedules combined procedures, stop billing 0660T alongside cataract codes for Aetna patients after January 16, 2026. The policy explicitly calls this experimental. Separate surgical sessions may be the only path to reimbursement for both procedures.

4. Update your charge capture to enforce the one-eye, one-time rule.
Neither Durysta nor iDose TR can be billed twice to the same eye. Build a charge capture check that flags any second claim for J7351 or J7355 on the same patient-eye combination. If you miss this, you get a denial and a potential compliance exposure.

5. Verify the dose units when billing J7351 and J7355.
HCPCS J7351 is billed per 1 mcg of bimatoprost. The policy cap is 10 mcg per eye — that's 10 units of J7351. HCPCS J7355 is billed per 1 mcg of travoprost. The cap is 75 mcg — that's 75 units of J7355. Submitting incorrect unit counts is a fast path to a claim denial or an audit.

6. Verify ICD-10 codes on every claim.
Covered diagnoses are open-angle glaucoma (H40.10X0–H40.159) and ocular hypertension (H40.51–H40.59). Any other diagnosis code — including angle-closure glaucoma or other variants — will not support coverage. Check your default diagnosis mapping before the effective date.

CPT, HCPCS, and ICD-10 Codes for Intracameral Implants Under CPB 1065

Covered HCPCS Codes (When Selection Criteria Are Met)

Other CPT Codes Related to CPB 1065

These codes are listed in the policy but are not explicitly covered under the current criteria. CPT 0661T (removal and reimplantation) is referenced but not included in any covered indication. Use with caution and expect scrutiny.

Key ICD-10-CM Diagnosis Codes

One note on the cataract codes (H25.011–H25.9): they appear in the code table but are not part of any covered indication under CPB 1065. Their presence likely reflects the related policy CPB 0484 on glaucoma surgery or the combined cataract-iDose TR scenario — which is explicitly not covered. Don't use cataract codes as the primary diagnosis for intracameral implant billing.